The role of xenobiotics in triggering psoriasis

Grželj, Jasna; Dolenc, Marija Sollner

doi:10.1007/s00204-020-02870-8

Cited by 16 publications

(28 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functional analysis of susceptibility loci has underlined roles of NFκB signalling, interferon signalling and Th1 -Th17 functions in psoriasis disease (11). Apart from genetics, adiposity, low cardiorespiratory fitness, depression, stress, smoking, infections, and drugs such as β-blockers, lithium, NSAIDs and ACE inhibitors (13,14) have been associated with an increase in psoriasis onset risk.…”

Section: Genetic Predisposition and Other Factors Influencing Disease Onsetmentioning

confidence: 99%

“…Psoriasis can also be triggered and exacerbated by various environmental stimuli and medication are among these. ß-Blockers, lithium, NSAIDs and ACE-inhibitors have been proposed to be psoriasis trigger factors (14). In this context comedication is important as it could have direct influence on psoriasis disease activity.…”

Section: Comorbidity and Comedicationmentioning

confidence: 99%

“…Pain may need to be addressed when assessing psoriasis in clinical practice -and should possibly influence treatment choice. NSAIDs have been proposed to trigger psoriasis; although the evidence is weak, this could also contribute to the results (14). In the brain the dorsal anterior cingulate cortex and the bilateral anterior insula are areas activated both when individuals experience pain but also social stress such as social rejection.…”

Section: Study IIImentioning

confidence: 99%

See 2 more Smart Citations

Different Aspects of Psoriasis : Comorbidity, Comedication and Disease Biomarkers

Duvetorp

2021

Linköping University Medical Dissertations

View full text Add to dashboard Cite

Section: Genetic Predisposition and Other Factors Influencing Disease Onsetmentioning

confidence: 99%

Section: Comorbidity and Comedicationmentioning

confidence: 99%

Section: Study IIImentioning

confidence: 99%

See 1 more Smart Citation

Different Aspects of Psoriasis : Comorbidity, Comedication and Disease Biomarkers

Duvetorp

2021

Linköping University Medical Dissertations

View full text Add to dashboard Cite

“…It is thus important for dermatologists to be aware of the likelihood of concomitant comorbid conditions and the possible impact of their associated inflammatory conditions. Physicians from other specialities should also be aware of the potential impact of their management strategies on psoriasis and the possible exacerbation of psoriasis by treatments prescribed for other conditions [49].…”

Section: Management and Preventionmentioning

confidence: 99%

Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis

Gmeiner¹,

Grželj²,

Štrukelj³

et al. 2020

View full text Add to dashboard Cite

Immense changes have been introduced in psoriasis treatment, including successful systemic treatment of inflammation and education of psoriatic patients. The focus of this review is the latest developments in the understanding of the aetiopathogenesis of psoriasis, the significance of its comorbidities, treatment possibilities and long-term management using the latest insight provided by pharmacogenetics and identification of biomarkers. The successful control of the disease leads to reduction of myocardial infarction and long-term cardiovascular risk but is usually achieved after various therapeutic attempts until the best-matched treatment for the individual is identified. There is a high unmet medical need for revealing biomarkers associated with disease prognosis, comorbidities, response to therapy and adverse effects. More studies have to be performed for identification and validation of biomarkers and implementation of personalized medicine into clinical practice.

show abstract

“…It can also be associated with inflammation of the tendon insertions 2 . Psoriatic lesions occur in a particular genetic terrain and a variety of environmental stimuli have been identified, such as infection, stress and medications 3–7 …”

Section: Introductionmentioning

confidence: 99%

Psoriasis risk after beta‐blocker exposure: Description of a pharmacovigilance signal

Azzouz

Guizelin

Lambert

et al. 2022

Brit J Clinical Pharma

View full text Add to dashboard Cite

Aim We aimed to investigate French pharmacovigilance data. The objective was to characterize psoriatic conditions that occurred after beta‐blocker (BB) exposure and bring to light a possible pharmacovigilance signal. Methods Spontaneous reports of psoriatic conditions recorded in the French National Pharmacovigilance Database (FPVD) between 1985 and 2019 were extracted. We performed a retrospective, descriptive analysis of reports linked to BB exposure. Association between psoriasis risk and BB exposure was assessed using a case/noncase study. Results Two hundred and twenty‐five reports of psoriatic conditions after BB exposure were recorded in the FPVD during the study period. Both cardioselective and noncardioselective, topical and systemic BBs are involved. Therapeutic indication of BB was mainly hypertension. Mean time to onset was 5 months and outcome was favourable in 68% after BB discontinuation. These features were concordant with those of literature reports. The reporting odds ratio (ROR) was 8.95 (95% confidence interval 7.75‐10.33). Conclusion We highlighted a statistically significant disproportionality which constitutes a pharmacovigilance signal. Psoriasis risk with BBs is a class effect. Increasing surveillance during the first year of BB exposure is needed.

show abstract

The role of xenobiotics in triggering psoriasis

Cited by 16 publications

References 210 publications

Different Aspects of Psoriasis : Comorbidity, Comedication and Disease Biomarkers

Different Aspects of Psoriasis : Comorbidity, Comedication and Disease Biomarkers

Psoriasis: A Comprehensive Review on the Aetiopathogenesis and Recent Advances in Long-Term Management of Patients with Plaque Psoriasis

Psoriasis risk after beta‐blocker exposure: Description of a pharmacovigilance signal

Contact Info

Product

Resources

About